Share

Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach

Alexandre Barbault, Frederico P Costa, Brad Bottger, Reginald F Munden, Fin Bomholt, Niels Kuster, Boris Pasche

PAPERmanualJ Exp Clin Cancer Res2009OtherEffect: mixedEvidence: Very low

Abstract

Purpose: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer. Patients and methods: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. Results: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57-92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). Conclusion: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. Trial registration: clinicaltrials.gov identifier NCT00805337.

AI evidence extraction

At a glance
Study type
Other
Effect direction
mixed
Population
Patients with various types of cancer; compassionate treatment in patients with advanced cancer and limited therapeutic options
Sample size
163
Exposure
ELF <1 MHz
Evidence strength
Very low
Confidence: 74% · Peer-reviewed: yes

Main findings

Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.

Outcomes measured

  • Identification of tumor-specific frequencies
  • Adverse events/toxicity (NCI grading)
  • Tumor response (complete response
  • partial response
  • stable disease)
  • Feasibility/tolerability of administering tumor-specific frequencies

Limitations

  • Noninvasive biofeedback method used to identify frequencies
  • details not provided in abstract
  • Compassionate-use treatment without stated control group
  • Only 13/28 treated patients were evaluable for response
  • Heterogeneous cancer types and metastatic sites
  • Duration of exposure/treatment regimen not specified in abstract
  • No SAR or field strength/exposure metrics reported in abstract
View raw extracted JSON
{
  "study_type": "other",
  "exposure": {
    "band": "ELF",
    "source": "therapeutic device/systemic delivery (amplitude-modulated electromagnetic fields)",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": null
  },
  "population": "Patients with various types of cancer; compassionate treatment in patients with advanced cancer and limited therapeutic options",
  "sample_size": 163,
  "outcomes": [
    "Identification of tumor-specific frequencies",
    "Adverse events/toxicity (NCI grading)",
    "Tumor response (complete response, partial response, stable disease)",
    "Feasibility/tolerability of administering tumor-specific frequencies"
  ],
  "main_findings": "Using a noninvasive biofeedback method, 1524 frequencies (0.1 Hz to 114 kHz) were identified in 163 cancer patients, with most frequencies (57–92%) reported as specific to a single tumor type. Compassionate treatment was offered to 28 patients; among 13 evaluable for response, 1 complete response (11 months), 1 partial response (13.5 months), and 4 cases of stable disease (4.0 to >34.1 months) were reported. Toxicity was limited to grade 1 fatigue in three patients, with no grade 2–4 toxicities reported.",
  "effect_direction": "mixed",
  "limitations": [
    "Noninvasive biofeedback method used to identify frequencies; details not provided in abstract",
    "Compassionate-use treatment without stated control group",
    "Only 13/28 treated patients were evaluable for response",
    "Heterogeneous cancer types and metastatic sites",
    "Duration of exposure/treatment regimen not specified in abstract",
    "No SAR or field strength/exposure metrics reported in abstract"
  ],
  "evidence_strength": "very_low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "amplitude-modulated electromagnetic fields",
    "tumor-specific frequencies",
    "biofeedback",
    "compassionate treatment",
    "advanced cancer",
    "0.1 Hz",
    "114 kHz",
    "feasibility",
    "toxicity",
    "clinical response"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.

NNEMF synthesis

Synthesis pending.

Original record: rfsafe.org paper 6737

Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach · Non-native EMF